Showing results (361-370 of 502) with videos related to
Sort By:
Pageof 51
Journal of Translational Medicine|May 5, 2016
Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancerTaofeek K Owonikoko, Guojing Zhang, Hyun S Kim, et al.Lung Cancer (Amsterdam, Netherlands)|March 8, 2025
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA studyMarina Chiara Garassino, Yong He, Myung-Ju Ahn, et al.Lung Cancer (Amsterdam, Netherlands)|November 19, 2019
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancerDavid E Gerber, D Ross Camidge, Daniel Morgensztern, et al.Cancer Cell|May 26, 2015
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer TherapyBingshe Han, Dongkyoo Park, Rui Li, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1Solange Peters, Meredith M Regan, Luis G Paz-Ares, et al.Clinical Lung Cancer|July 13, 2019
Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer DatabaseSibo Tian, Xinyan Zhang, Renjian Jiang, et al.Nature Cancer|November 11, 2024
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein exportBrajendra K Tripathi, Nicole H Hirsh, Xiaolan Qian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2018
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung CancerThanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2026
Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L)Suresh S Ramalingam, Vamsidhar Velcheti, Mehmet Altan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2017
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung CancerSuresh S Ramalingam, James C-H Yang, Chee Khoon Lee, et al.Pageof 51